Společnost Biosidus rozšiřuje výrobní kapacitu biologických léčiv a posiluje globální dodavatelské kapacity pro agalsidázu beta

agalsidase betaPositive

AI Analysis

Summary

Biosidus announced the commissioning of a new bioreactor facility to expand manufacturing capacity for agalsidase beta biosimilar and strengthen global supply capabilities.

Outcome Details

New bioreactor facility commissioned

Importance:3/10

Sentiment:

0.60

manufacturingcapacity expansionbiosimilaragalsidase betaArgentina

Read the original article

Published by PR Newswire Biotech on August 27, 2026 8:58 AM

Read Original